Informação sobre produto
- (5E)-6-[3-[[(Cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid
- 5-Hexenoic acid, 6-[3-[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-, (E)-
- 5-Hexenoic acid, 6-[3-[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-, (5E)-
- (5E)-6-[m-(3-tert-Butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)-5-hexenoic acid
Terbogrel is a chemical compound that has been used as a pharmaceutical agent. It is an ester of terbutaline and benzoic acid. Terbogrel is used to treat heparin-induced thrombocytopenia and to prevent deep vein thrombosis (DVT). The pharmacological mechanism of terbogrel is not fully elucidated, but it is believed that the drug increases the production of prostacyclin, which inhibits platelet aggregation. Terbogrel also has antioxidant properties due to its hydroxyl group that may be important for the prevention of oxidative injury in collagen synthesis. Terbogrel has been shown to have clinical relevance in primary pulmonary hypertension, which can be treated with this drug. Terbogrel binds to phosphodiesterase type-5, preventing the breakdown of cAMP and PDE-3. This binding leads to increased levels of cAMP, which stimulates protein kinase A (PKA
Propriedades químicas
Consulta técnica sobre: 3D-ZFA97974 Terbogrel
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
